Galea Life Sciences

Galea Therapeutics is a biotechnology company dedicated to developing next-generation RNA-based medicines for central nervous system (CNS) disorders. The company utilizes a proprietary delivery platform designed to overcome the blood-brain barrier and achieve widespread distribution of therapeutic oligonucleotides throughout the brain and spinal cord. By leveraging advanced medicinal chemistry and RNA interference (RNAi) technology, Galea aims to treat devastating neurological conditions that currently lack effective therapies. Their pipeline focuses on neurodegenerative diseases and rare genetic disorders of the brain, such as Huntington's disease and ALS. The company was founded by world-renowned experts in RNA chemistry and neuroscience from the UMass Chan Medical School and is backed by leading life sciences investors.